ClinicalTrials.gg
CompletedNCT05561751Updated Nov 19, 2026Results posted

Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

A Phase 2 interventional study of GPC-100 and Propranolol in Multiple Myeloma, sponsored by GPCR Therapeutics, Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by GPCR Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Updated Nov 19, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,168 studies in Multiple Myeloma with a site in United States — 273 open to participants now, 501 under way, 66 of them phase 3. Multiple Myeloma · United States.

Enrollment
1,161st of 1,901
28 · median 36
Started
2023
with 83 others
Phase 2
751 of 2,168
74 open now
Registered
1,862nd of 2,168
by date

Among the 2,168 studies in Multiple Myeloma with a site in United States, this one is the 1,161st largest by enrollment of the 1,901 interventional ones that give a count, is one of 84 that started in 2023, is one of 751 in phase 2, and was the 1,862nd registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

273 of the 2,168 studies in Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:

268 more — sign in →

All 273 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,168 studies in Multiple Myeloma with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, open-label study. Patients will be screened within 28 days prior to the study drug administration. Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration.

Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arms:

  • GPC-100 in combination with propranolol; or
  • GPC-100 in combination with propranolol and G-CSF. To characterize the safety and clinical activity of GPC-100, the study will employ a Bayesian Optimal Phase II (BOP2) design to enroll patients for each arm.

All patients will receive via IV 3.14 mg/kg GPC-100 (Burixafor) at least 2 hours prior to leukapheresis sessions from Days 7-8 (Days 9-11 optional) and 30 mg propranolol (3 x 10 mg tablets) twice daily at 8:30 AM (+/- 1 hr) and 4:00 PM (+/- 1 hr) local time from Days 1 to 8 (and on Days 9-11, if applicable). Patients will administer the first dose of propranolol onsite on Day 1. Patients will be provided with doses of propranolol for self-administration at time points when they are not otherwise required to be onsite. Sites should contact patients via telephone to confirm propranolol administration for doses administered outside of clinic.

Read the detailed description

This is a randomized, open-label study. Patients will be screened within 28 days prior to the study drug administration. Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration.

Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arms:

  • GPC-100 in combination with propranolol; or
  • GPC-100 in combination with propranolol and G-CSF. To characterize the safety and clinical activity of GPC-100, the study will employ a Bayesian Optimal Phase II (BOP2) design to enroll patients for each arm.

All patients via IV 3.14 mg/kg GPC-100 (Burixafor) at least 2 hours prior to leukapheresis sessions from Days 7-8 (Days 9-11 optional) and 30 mg propranolol (3 x 10 mg tablets) twice daily at 8:30 AM (+/- 1 hr) and 4:00 PM (+/- 1 hr) local time from Days 1 to 8 (and on Days 9-11, if applicable). Patients will administer the first dose of propranolol onsite on Day 1. Patients will be provided with doses of propranolol for self-administration at time points when they are not otherwise required to be onsite. Sites should contact patients via telephone to confirm propranolol administration for doses administered outside of clinic.

Only patients randomized to the treatment arm receiving GPC-100 in combination with propranolol and G-CSF will receive SC injections of 10 microgram/kg/day G-CSF at 5:00 PM (+/- 3 hr) local time on Days 3 to 7. Patients in this arm will receive G-CSF injections on Days 8-10 at 5:00 PM (+/- 3 hr) local time only if they will undergo the optional third-fifth days of mobilization/collection (Days 9-11) at the Investigator's discretion.

On Days 7 and 8 (and on Days 9-11, if applicable), the patient will receive a morning 30 mg propranolol dose (3 x 10 mg tablets) followed immediately by a 3.14 mg/kg dose of GPC-100 free base (active ingredient) and will start collection of CD34+ stem cells via leukapheresis.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

To be eligible to participate in this study, patients must meet all the following criteria:

  1. Male or female, greater than or equal to18 years of age;
  2. Patients with diagnosis of MM per the International Myeloma Working Group criteria ;
  3. Eligible for at the Investigator's discretion;
  4. >4 weeks since completion of last cycle of chemotherapy prior to Day 1;
  5. Patient must be on first or second complete response or partial response;
  6. performance status of 0 or 1 (see Appendix C);
  7. Systolic blood pressure (SBP) 100 - 160 mmHg inclusive, and diastolic blood pressure (DBP) 60 - 100 mmHg inclusive;
  8. ANC greater than or equal to1.0 x 109/L on Screening laboratory assessments;
  9. count greater than or equal to100 x 109/L on Screening laboratory assessments;
  10. greater than or equal to 30 ml/min, as calculated according to the Cockcroft-Gault formula;
  11. and alanine aminotransferase less than or equal to 2 x (ULN) and total less than or equal to1.5 x ULN on Screening laboratory assessments;
  12. Adequate cardiac ( [LVEF] greater than or equal to 50%) and pulmonary function (room air O2 saturation value greater than or equal to 92%);
  13. For females, 1 of the following criteria must be fulfilled:

    1. At least 1 year ; or
    2. Surgically sterile, or willing to use a double-barrier method of (e.g., intrauterine device plus condom, spermicidal gel plus condom) from Day 1 until 28 days after the last dose of GPC-100.
  14. Males must be willing to use a reliable form of contraception (e.g., use of a condom or a partner fulfilling the above criteria) from Day 1 until 28 days after the last dose of GPC-100; and
  15. Patients must be willing and able to provide signed . 4.2 Exclusion Criteria

Patients must be excluded if they meet any of the following criteria:

  1. greater than or equal to 25% of BM irradiated within 5 years prior to Day 1 (see Appendix D);
  2. No more than one year of therapy administered prior to stem cell mobilization, per institution standards;
  3. Patients who have undergone previous stem cell transplant;
  4. Receipt of G-CSF within 2 weeks prior to Day 1;
  5. History of another except for the following:

    1. Adequately treated local basal cell or squamous cell carcinoma of the skin;
    2. Adequately treated carcinoma in situ of the cervix without evidence of disease;
    3. Adequately treated papillary, noninvasive bladder cancer; or
    4. Low-grade prostate cancer that is on active surveillance and not expected to clinically progress over 2 years.
  6. Patients who are on BBs and unable to switch therapy; Note: Patients on BBs who are able to switch therapy will undergo a gradual tapering of their current BB under the guidance of the Investigator. At the Investigator's discretion, the initial days of propranolol administration may be permitted to overlap with the final days of tapering of the previous BB. Patients may not be treated with cardiovascular drugs that would interact with propranolol including angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, and alpha blockers at study enrollment and while on propranolol during the study.
  7. Patients with severe asthma who require beta agonist therapy;
  8. History of poor and uncontrolled cardiovascular or pulmonary disease such as myocardial infarction, cardiac arrhythmias, , congestive heart failure ( heart failure class >2), stroke, unexplained syncope, or ;
  9. History of long syndrome or torsade de pointes;
  10. Patients with a QTcF >470 msec or PR interval >280 msec on Screening 12-lead (ECG);
  11. Active infection requiring treatment in the 7 days before Day 1;
  12. Positive polymerase chain reaction test from nasal specimen for SARS-CoV-2 within 7 days prior to Day 1;
  13. Pregnant or breastfeeding;
  14. Known psychiatric or substance abuse disorder that would interfere with Protocol compliance;
  15. Receipt of any other drug or device within 1 month before Day 1; or
  16. Receipt of prior treatment with CXCR4 inhibitor for stem cell collection.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    GPC-100 in combination with propranolol;

    Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arm: • GPC-100 in combination with propranolol; or

    Drug: GPC-100 · Drug: Propranolol

  • Experimental
    GPC-100 in combination with propranolol and G-CSF

    Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arm: • GPC-100 in combination with propranolol and G-CSF.

    Drug: GPC-100 · Drug: Propranolol · Drug: G-CSF

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of Participants That Achieve >=2 x 10^6 CD34+ Cells/kg in 2 Leukapheresis Sessions

    Participants achieving a cumulative collection of \>=2 x 10\^6 CD34+ cells/kg within 2 leukapheresis sessions

    Time frame: First two leukapheresis sessions (study days 7 and 8)

07

Results

Posted Nov 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneGPC-100 in Combination With PropranololGPC-100 in Combination With Propranolol and G-CSF
Started424
Treated with any drug421
Received gpc-100 and underwent ≥1 leukapheresis collection419
Underwent autologous stem cell transplantation (asct)118
Completed417
Not completed07
Withdrew: Physician decision02
Withdrew: Adverse event01
Withdrew: Transferred care and declined further study follow-up01
Withdrew: Withdrawal by subject01
Withdrew: Death01
Withdrew: Eligibility criteria not met prior to dosing01

Outcome measures

PrimaryProportion of Participants That Achieve >=2 x 10^6 CD34+ Cells/kg in 2 Leukapheresis Sessions

Participants achieving a cumulative collection of \>=2 x 10\^6 CD34+ cells/kg within 2 leukapheresis sessions

Time frame:
First two leukapheresis sessions (study days 7 and 8)
Reported as:
Count of participants · Participants
Proportion of Participants That Achieve >=2 x 10^6 CD34+ Cells/kg in 2 Leukapheresis Sessions
ParticipantsGPC-100 in Combination With PropranololGPC-100 in Combination With Propranolol and G-CSF
Proportion of Participants That Achieve >=2 x 10^6 CD34+ Cells/kg in 2 Leukapheresis Sessions017

Adverse events

Collected over From informed consent through 28 days after the last dose of GPC-100 (up to 63 days), or through Day 100 post-transplant for participants who underwent ASCT (up to 161 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GPC-100 in Combination With Propranolol0/4 (0%)0/4 (0%)4/4 (100%)
GPC-100 in Combination With Propranolol and G-CSF1/21 (4.8%)3/21 (14.3%)21/21 (100%)
Most frequent serious events
Most frequent serious events
EventGPC-100 in Combination With PropranololGPC-100 in Combination With Propranolol and G-CSF
Rhinovirus InfectionInfections and infestations0/41/21
Failure to ThriveMetabolism and nutrition disorders0/41/21
Cardiac arrestCardiac disorders0/41/21
Most frequent other events
Showing 10 of 63
Most frequent other events
EventGPC-100 in Combination With PropranololGPC-100 in Combination With Propranolol and G-CSF
DiarrheaGastrointestinal disorders1/411/21
Decreased platelet countInvestigations1/411/21
FatigueGeneral disorders2/48/21
AnaemiaBlood and lymphatic system disorders1/410/21
NauseaGastrointestinal disorders1/49/21
Febrile NeutropeniaBlood and lymphatic system disorders0/47/21
Decreased white blood cell countInvestigations1/47/21
Decreased neutrophil countInvestigations1/47/21
Bone PainMusculoskeletal and connective tissue disorders0/47/21
ThrombocytopeniaBlood and lymphatic system disorders0/46/21

Baseline characteristics

Baseline characteristics are summarized for the enrolled participants (Intent-to-Treat Analysis Set)

Age, Categorical
Age, Categorical(Participants)GPC-100 in Combination With PropranololGPC-100 in Combination With Propranolol and G-CSFTotal
<=18 years000
Between 18 and 65 years41014
>=65 years01414
Age, Continuous
Age, Continuous(Years)GPC-100 in Combination With PropranololGPC-100 in Combination With Propranolol and G-CSFTotal
Median56.5 (51 to 64)68.5 (42 to 78)65.5 (42 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)GPC-100 in Combination With PropranololGPC-100 in Combination With Propranolol and G-CSFTotal
Female189
Male31619
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GPC-100 in Combination With PropranololGPC-100 in Combination With Propranolol and G-CSFTotal
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White41822
More than one race011
Unknown or Not Reported033
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GPC-100 in Combination With PropranololGPC-100 in Combination With Propranolol and G-CSFTotal
Hispanic or Latino055
Not Hispanic or Latino41721
Unknown or Not Reported022
08

Study locations

10 sites
  • University of California, San Diego (UCSD) - Moores Cancer Center
    La Jolla, California 92037, United States
  • University of Florida (UF) - Shands Cancer Center
    Gainesville, Florida 32608, United States
  • Indiana Blood and Marrow Transplantation
    Indianapolis, Indiana 46077, United States
  • University of Massachusetts
    Worcester, Massachusetts 01655, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • John Theurer Cancer Center At Hackensack UMC
    Hackensack, New Jersey 07601, United States
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Virginia Commonwealth University - Massey Cancer Center
    Richmond, Virginia 23284, United States
09

References and documents

Publications

  • Sukhtankar DD, Fung JJ, Kim MN, Cayton T, Chiou V, Caculitan NG, Zalicki P, Kim S, Jo Y, Kim S, Lee JM, Choi J, Mun S, Chin A, Jang Y, Lee JY, Kim G, Kim EH, Huh WK, Jeong JY, Seen DS, Cardarelli PM. GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranolol. PLoS One. 2023 Oct 25;18(10):e0287863. doi: 10.1371/journal.pone.0287863. eCollection 2023. PubMed 37878624 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Sep 2025, 31 months.

Results were first posted in Nov 2026, 1 year 1 month after primary completion.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 31 months is below that.

Counting every sponsor, half of 504 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2022
First posted
Sep 30, 2022
StartActual
Feb 13, 2023
Primary completionActual
Sep 30, 2025
CompletionActual
Oct 31, 2025
Results first posted
Nov 19, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 19, 2026
Enrollment
30→28
Nov 19, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedProportion of patients that achieveParticipants That Achieve >=2 x 10^6 CD34+ cellsCells/kg in 2 leukapheresis sessionsLeukapheresis SessionsTime frame: 2 days → First two leukapheresis sessions (study days 7 and 8)
Nov 19, 2026
Documents
Show all 1 update
  1. Nov 19, 2026
    Results posted
    Enrollment 30→28
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProportion of patients that achieveParticipants That Achieve >=2 x 10^6 CD34+ cellsCells/kg in 2 leukapheresis sessionsLeukapheresis SessionsTime frame: 2 days → First two leukapheresis sessions (study days 7 and 8)
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05561751
Lead sponsor
GPCR Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 30, 2022
Start date
Feb 13, 2023
Primary completion
Sep 30, 2025
Completion
Oct 31, 2025
Results posted
Nov 19, 2026
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Propranolol

Start the discussion